Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 160 entries
Sorted by: Best Match Show Resources per page
Legal highs: staying on top of the flood of novel psychoactive substances.

Therapeutic advances in psychopharmacology

Baumeister D, Tojo LM, Tracy DK.
PMID: 26240749
Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539.

There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called 'legal highs', which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown...

Cite
Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97-132doi: 10.1177/2045125314559539.
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015). Legal highs: staying on top of the flood of novel psychoactive substances. Therapeutic advances in psychopharmacology, 5(2), 97-132. https://doi.org/10.1177/2045125314559539
Baumeister, David, et al. "Legal highs: staying on top of the flood of novel psychoactive substances." Therapeutic advances in psychopharmacology vol. 5,2 (2015): 97-132. doi: https://doi.org/10.1177/2045125314559539
Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015 Apr;5(2):97-132. doi: 10.1177/2045125314559539. PMID: 26240749; PMCID: PMC4521440.
Copy Download .nbib Format: NLM
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder.

Frontiers in pharmacology

Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE.
PMID: 29515439
Front Pharmacol. 2018 Feb 20;9:100. doi: 10.3389/fphar.2018.00100. eCollection 2018.

After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted...

Cite
Bogenschutz MP, Podrebarac SK, Duane JH, et al. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol. 2018;9:100doi: 10.3389/fphar.2018.00100.
Bogenschutz, M. P., Podrebarac, S. K., Duane, J. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., Ross, S., & Mennenga, S. E. (2018). Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Frontiers in pharmacology, 9100. https://doi.org/10.3389/fphar.2018.00100
Bogenschutz, Michael P, et al. "Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder." Frontiers in pharmacology vol. 9 (2018): 100. doi: https://doi.org/10.3389/fphar.2018.00100
Bogenschutz MP, Podrebarac SK, Duane JH, Amegadzie SS, Malone TC, Owens LT, Ross S, Mennenga SE. Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Front Pharmacol. 2018 Feb 20;9:100. doi: 10.3389/fphar.2018.00100. eCollection 2018. PMID: 29515439; PMCID: PMC5826237.
Copy Download .nbib Format: NLM
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions.

Frontiers in pharmacology

Nielson EM, May DG, Forcehimes AA, Bogenschutz MP.
PMID: 29515449
Front Pharmacol. 2018 Feb 21;9:132. doi: 10.3389/fphar.2018.00132. eCollection 2018.

Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence. Detailed description of the content and methods of psychedelic-assisted psychotherapy, as it is conducted in clinical settings, is scarce.

Cite
Nielson EM, May DG, Forcehimes AA, et al. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Front Pharmacol. 2018;9:132doi: 10.3389/fphar.2018.00132.
Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Frontiers in pharmacology, 9132. https://doi.org/10.3389/fphar.2018.00132
Nielson, Elizabeth M, et al. "The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions." Frontiers in pharmacology vol. 9 (2018): 132. doi: https://doi.org/10.3389/fphar.2018.00132
Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Front Pharmacol. 2018 Feb 21;9:132. doi: 10.3389/fphar.2018.00132. eCollection 2018. PMID: 29515449; PMCID: PMC5826346.
Copy Download .nbib Format: NLM
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics.

Frontiers in pharmacology

Schindler EAD, Wallace RM, Sloshower JA, D'Souza DC.
PMID: 29545753
Front Pharmacol. 2018 Mar 01;9:177. doi: 10.3389/fphar.2018.00177. eCollection 2018.

Recent reports on the effects of psychedelic-assisted therapies for mood disorders and addiction, as well as the effects of psychedelics in the treatment of cluster headache, have demonstrated promising therapeutic results. In addition, the beneficial effects appear to persist...

Cite
Schindler EAD, Wallace RM, Sloshower JA, et al. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Front Pharmacol. 2018;9:177doi: 10.3389/fphar.2018.00177.
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A., & D'Souza, D. C. (2018). Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers in pharmacology, 9177. https://doi.org/10.3389/fphar.2018.00177
Schindler, Emmanuelle A D, et al. "Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics." Frontiers in pharmacology vol. 9 (2018): 177. doi: https://doi.org/10.3389/fphar.2018.00177
Schindler EAD, Wallace RM, Sloshower JA, D'Souza DC. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Front Pharmacol. 2018 Mar 01;9:177. doi: 10.3389/fphar.2018.00177. eCollection 2018. PMID: 29545753; PMCID: PMC5838010.
Copy Download .nbib Format: NLM
Phytochemical investigation of natural and in vitro raised Vṛddhadāruka plants.

Ancient science of life

Bharati AJ, Bansal YK.
PMID: 25861141
Anc Sci Life. 2014 Oct-Dec;34(2):80-4. doi: 10.4103/0257-7941.153463.

BACKGROUND: Argyreia nervosa commonly known as elephant creeper (English) and Vṛddhadāruka (Sanskrit) is a woody climber that belongs to the family Convolvulaceae. Seeds of this plant contain hallucinogens including ergot alkaloids and a naturally occurring lysergic acid amide. Traditionally...

Cite
Bharati AJ, Bansal YK. Phytochemical investigation of natural and in vitro raised Vṛddhadāruka plants. Anc Sci Life. 2014;34(2):80-4doi: 10.4103/0257-7941.153463.
Bharati, A. J., & Bansal, Y. K. (2014). Phytochemical investigation of natural and in vitro raised Vṛddhadāruka plants. Ancient science of life, 34(2), 80-4. https://doi.org/10.4103/0257-7941.153463
Bharati, Asha Jyoti, and Bansal, Yogendra Kumar. "Phytochemical investigation of natural and in vitro raised Vṛddhadāruka plants." Ancient science of life vol. 34,2 (2014): 80-4. doi: https://doi.org/10.4103/0257-7941.153463
Bharati AJ, Bansal YK. Phytochemical investigation of natural and in vitro raised Vṛddhadāruka plants. Anc Sci Life. 2014 Oct-Dec;34(2):80-4. doi: 10.4103/0257-7941.153463. PMID: 25861141; PMCID: PMC4389397.
Copy Download .nbib Format: NLM
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Therapeutic advances in psychopharmacology

Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE.
PMID: 27354908
Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213. doi: 10.1177/2045125316638008. Epub 2016 Mar 18.

To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic...

Cite
Dos Santos RG, Osório FL, Crippa JA, et al. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016;6(3):193-213doi: 10.1177/2045125316638008.
Dos Santos, R. G., Osório, F. L., Crippa, J. A., Riba, J., Zuardi, A. W., & Hallak, J. E. (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic advances in psychopharmacology, 6(3), 193-213. https://doi.org/10.1177/2045125316638008
Dos Santos, Rafael G, et al. "Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years." Therapeutic advances in psychopharmacology vol. 6,3 (2016): 193-213. doi: https://doi.org/10.1177/2045125316638008
Dos Santos RG, Osório FL, Crippa JA, Riba J, Zuardi AW, Hallak JE. Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol. 2016 Jun;6(3):193-213. doi: 10.1177/2045125316638008. Epub 2016 Mar 18. PMID: 27354908; PMCID: PMC4910400.
Copy Download .nbib Format: NLM
Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA).

Behavioural pharmacology

Broadbent J, Appel JB, Michael EK, Ricker JH.
PMID: 11224147
Behav Pharmacol. 1992 Oct;3(5):443-454.

The isomers of 3,4-methylenedioxyamphetamine (MDA) functioned as discriminative stimuli in rats trained to discriminate either (-) MDA (1.25mg/kg) or (+) MDA (1.25mg/kg) from saline. Dose- and time-response curves indicated that drug lever selection occurred at doses of at least...

Cite
Broadbent J, Appel JB, Michael EK, et al. Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA). Behav Pharmacol. 1992;3(5):443-454
Broadbent, J., Appel, J. B., Michael, E. K., & Ricker, J. H. (1992). Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA). Behavioural pharmacology, 3(5), 443-454.
Broadbent, J., et al. "Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA)." Behavioural pharmacology vol. 3,5 (1992): 443-454.
Broadbent J, Appel JB, Michael EK, Ricker JH. Discriminative stimulus effects of the optical isomers of 3,4-methylenedioxyamphetamine (MDA). Behav Pharmacol. 1992 Oct;3(5):443-454. PMID: 11224147.
Copy Download .nbib Format: NLM
Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA).

Behavioural pharmacology

Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB.
PMID: 11224335
Behav Pharmacol. 1995 Apr;6(3):263-275.

The discriminative stimulus effects of the stereoisomers of 3,4-methylenedioxymethamphetamine (MDMA) were studied in rats trained to discriminate 1.25mg/kg of (+)-MDMA or 3.5mg/kg of (-)-MDMA from saline, in a two lever, water-reinforced, drug discrimination situation. The isomers of MDMA and...

Cite
Baker LE, Broadbent J, Michael EK, et al. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol. 1995;6(3):263-275
Baker, L. E., Broadbent, J., Michael, E. K., Matthews, P. K., Metosh, C. A., Saunders, R. B., West, W. B., & Appel, J. B. (1995). Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behavioural pharmacology, 6(3), 263-275.
Baker, L.E., et al. "Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA)." Behavioural pharmacology vol. 6,3 (1995): 263-275.
Baker LE, Broadbent J, Michael EK, Matthews PK, Metosh CA, Saunders RB, West WB, Appel JB. Assessment of the discriminative stimulus effects of the optical isomers of ecstasy (3,4-methylenedioxymethamphetamine; MDMA). Behav Pharmacol. 1995 Apr;6(3):263-275. PMID: 11224335.
Copy Download .nbib Format: NLM
[Anesthesia and the Ecstasy user.].

Revista brasileira de anestesiologia

Moro ET, Ferraz AA, Módolo NS.
PMID: 19468565
Rev Bras Anestesiol. 2006 Apr;56(2):183-8. doi: 10.1590/s0034-70942006000200010.

BACKGROUND AND OBJECTIVES: The number of new users of illicit substances has been growing steadily all over the world over the last few years. Marijuana and cocaine have been mentioned most often, but the last few years saw a...

Cite
Moro ET, Ferraz AA, Módolo NS. Anestesia e o usuário de Ecstasy. [Anesthesia and the Ecstasy user.]. Rev Bras Anestesiol. 2006;56(2):183-8doi: 10.1590/s0034-70942006000200010.
Moro, E. T., Ferraz, A. A., & Módolo, N. S. (2006). Anestesia e o usuário de Ecstasy. [Anesthesia and the Ecstasy user.]. Revista brasileira de anestesiologia, 56(2), 183-8. https://doi.org/10.1590/s0034-70942006000200010
Moro, Eduardo Toshiyuki, et al. "Anestesia e o usuário de Ecstasy." [Anesthesia and the Ecstasy user.]. Revista brasileira de anestesiologia vol. 56,2 (2006): 183-8. doi: https://doi.org/10.1590/s0034-70942006000200010
Moro ET, Ferraz AA, Módolo NS. Anestesia e o usuário de Ecstasy. [Anesthesia and the Ecstasy user.]. Rev Bras Anestesiol. 2006 Apr;56(2):183-8. doi: 10.1590/s0034-70942006000200010. Portuguese. PMID: 19468565.
Copy Download .nbib Format: NLM
Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia.

Harm reduction journal

Buadze A, Stohler R, Schulze B, Schaub M, Liebrenz M.
PMID: 20920183
Harm Reduct J. 2010 Sep 28;7:22. doi: 10.1186/1477-7517-7-22.

BACKGROUND: There has been a considerable amount of debate among the research community whether cannabis use may cause schizophrenia and whether cannabis use of patients with schizophrenia is associated with earlier and more frequent relapses. Considering that studies exploring...

Cite
Buadze A, Stohler R, Schulze B, et al. Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia. Harm Reduct J. 2010;7:22doi: 10.1186/1477-7517-7-22.
Buadze, A., Stohler, R., Schulze, B., Schaub, M., & Liebrenz, M. (2010). Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia. Harm reduction journal, 722. https://doi.org/10.1186/1477-7517-7-22
Buadze, Anna, et al. "Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia." Harm reduction journal vol. 7 (2010): 22. doi: https://doi.org/10.1186/1477-7517-7-22
Buadze A, Stohler R, Schulze B, Schaub M, Liebrenz M. Do patients think cannabis causes schizophrenia? - A qualitative study on the causal beliefs of cannabis using patients with schizophrenia. Harm Reduct J. 2010 Sep 28;7:22. doi: 10.1186/1477-7517-7-22. PMID: 20920183; PMCID: PMC2954921.
Copy Download .nbib Format: NLM
Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin.

Journal for the scientific study of religion

Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR.
PMID: 23316089
J Sci Study Relig. 2012 Dec;51(4):721-737. doi: 10.1111/j.1468-5906.2012.01685.x.

A large body of historical evidence describes the use of hallucinogenic compounds, such as psilocybin mushrooms, for religious purposes. But few scientific studies have attempted to measure or characterize hallucinogen-occasioned spiritual experiences. The present study examined the factor structure...

Cite
Maclean KA, Leoutsakos JM, Johnson MW, et al. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig. 2012;51(4):721-737doi: 10.1111/j.1468-5906.2012.01685.x.
Maclean, K. A., Leoutsakos, J. M., Johnson, M. W., & Griffiths, R. R. (2012). Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. Journal for the scientific study of religion, 51(4), 721-737. https://doi.org/10.1111/j.1468-5906.2012.01685.x
Maclean, Katherine A, et al. "Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin." Journal for the scientific study of religion vol. 51,4 (2012): 721-737. doi: https://doi.org/10.1111/j.1468-5906.2012.01685.x
Maclean KA, Leoutsakos JM, Johnson MW, Griffiths RR. Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. J Sci Study Relig. 2012 Dec;51(4):721-737. doi: 10.1111/j.1468-5906.2012.01685.x. PMID: 23316089; PMCID: PMC3539773.
Copy Download .nbib Format: NLM
Drug use among youth and adults in a population-based survey in South Africa.

The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa

Peltzer K, Phaswana-Mafuya N.
PMID: 30263218
S Afr J Psychiatr. 2018 Apr 12;24:1139. doi: 10.4102/sajpsychiatry.v24i0.1139. eCollection 2018.

OBJECTIVE: Illicit drug use is a growing public health problem. The aim of the study was to assess the prevalence of drug use and the sociodemographic and health characteristics that influence it among young and adult South Africans.METHODS: Data...

Cite
Peltzer K, Phaswana-Mafuya N. Drug use among youth and adults in a population-based survey in South Africa. S Afr J Psychiatr. 2018;24:1139doi: 10.4102/sajpsychiatry.v24i0.1139.
Peltzer, K., & Phaswana-Mafuya, N. (2018). Drug use among youth and adults in a population-based survey in South Africa. The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa, 241139. https://doi.org/10.4102/sajpsychiatry.v24i0.1139
Peltzer, Karl, and Phaswana-Mafuya, Nancy. "Drug use among youth and adults in a population-based survey in South Africa." The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa vol. 24 (2018): 1139. doi: https://doi.org/10.4102/sajpsychiatry.v24i0.1139
Peltzer K, Phaswana-Mafuya N. Drug use among youth and adults in a population-based survey in South Africa. S Afr J Psychiatr. 2018 Apr 12;24:1139. doi: 10.4102/sajpsychiatry.v24i0.1139. eCollection 2018. PMID: 30263218; PMCID: PMC6138152.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 160 entries